loading
An 2 Therapeutics Inc stock is traded at $1.15, with a volume of 69,956. It is up +3.60% in the last 24 hours and up +3.60% over the past month. AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
See More
Previous Close:
$1.11
Open:
$1.09
24h Volume:
69,956
Relative Volume:
0.36
Market Cap:
$31.43M
Revenue:
-
Net Income/Loss:
$-37.38M
P/E Ratio:
-0.9274
EPS:
-1.24
Net Cash Flow:
$-35.50M
1W Performance:
+7.48%
1M Performance:
+3.60%
6M Performance:
+1.77%
1Y Performance:
+3.60%
1-Day Range:
Value
$1.09
$1.16
1-Week Range:
Value
$1.08
$1.17
52-Week Range:
Value
$0.975
$1.675

An 2 Therapeutics Inc Stock (ANTX) Company Profile

Name
Name
An 2 Therapeutics Inc
Name
Phone
(650) 331-9090
Name
Address
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Name
Employee
36
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ANTX's Discussions on Twitter

Compare ANTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ANTX
An 2 Therapeutics Inc
1.15 30.61M 0 -37.38M -35.50M -1.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-09-24 Downgrade Evercore ISI In-line → Underperform
Aug-09-24 Downgrade Leerink Partners Outperform → Market Perform
Jul-03-24 Upgrade Leerink Partners Market Perform → Outperform
Apr-02-24 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Feb-13-24 Downgrade Leerink Partners Outperform → Market Perform
Feb-12-24 Downgrade Evercore ISI Outperform → In-line
Feb-12-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-12-24 Downgrade Oppenheimer Outperform → Perform
Jan-04-24 Initiated JMP Securities Mkt Outperform
Jul-18-22 Resumed Oppenheimer Outperform
View All

An 2 Therapeutics Inc Stock (ANTX) Latest News

pulisher
Aug 20, 2025

Mountain Crest Acquisition Corp. II/Better Therapeutics, Inc. Class Action – Important Settlement Information - Business Wire

Aug 20, 2025
pulisher
Aug 19, 2025

Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell (VKTX) - Seeking Alpha

Aug 19, 2025
pulisher
Aug 19, 2025

Viking Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Aug 19, 2025
pulisher
Aug 19, 2025

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - PR Newswire

Aug 19, 2025
pulisher
Aug 15, 2025

Capricor Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationCAPR - The Malaysian Reserve

Aug 15, 2025
pulisher
Aug 14, 2025

Plus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2025
pulisher
Aug 14, 2025

Xilio Therapeutics shares fall 2.52% intraday after announcing updated Phase 2 data for vilastobart. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - PR Newswire

Aug 14, 2025
pulisher
Aug 14, 2025

Candel Therapeutics, Inc. SEC 10-Q Report - TradingView

Aug 14, 2025
pulisher
Aug 14, 2025

BRAINSTORM CELL THERAPEUTICS INC. SEC 10-Q Report - TradingView

Aug 14, 2025
pulisher
Aug 14, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - Yahoo Finance

Aug 14, 2025
pulisher
Aug 14, 2025

Werewolf Therapeutics, Inc. SEC 10-Q Report - TradingView

Aug 14, 2025
pulisher
Aug 13, 2025

Allogene Therapeutics, Inc. SEC 10-Q Report - TradingView

Aug 13, 2025
pulisher
Aug 13, 2025

Allogene Therapeutics Advances Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma and Initiates Phase 1 Trials for Autoimmune Disease and Renal Cell Carcinoma - Quiver Quantitative

Aug 13, 2025
pulisher
Aug 13, 2025

Compass Therapeutics And 2 Other Promising Penny Stocks To Consider - simplywall.st

Aug 13, 2025
pulisher
Aug 12, 2025

Cognition Therapeutics Receives End-of-Phase 2 Meeting - GlobeNewswire

Aug 12, 2025
pulisher
Aug 06, 2025

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Aug 06, 2025
pulisher
Aug 05, 2025

Windtree Therapeutics, Inc. Reports Positive Interim Analysis for Istaroxime in Phase 2 Study of Cardiogenic Shock - Quiver Quantitative

Aug 05, 2025
pulisher
Aug 05, 2025

Akebia Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView

Aug 05, 2025
pulisher
Aug 02, 2025

BioXcel Therapeutics Completes Phase 3 Trial, Awaits FDA Decision - StocksToTrade

Aug 02, 2025
pulisher
Aug 02, 2025

Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN

Aug 02, 2025
pulisher
Aug 01, 2025

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire

Aug 01, 2025
pulisher
Jul 30, 2025

United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results - Business Wire

Jul 30, 2025
pulisher
Jul 25, 2025

Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy - Yahoo Finance

Jul 25, 2025
pulisher
Jul 22, 2025

Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Newsfile

Jul 22, 2025
pulisher
Jul 16, 2025

Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - GlobeNewswire

Jul 16, 2025
pulisher
Jul 15, 2025

Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st

Jul 15, 2025
pulisher
Jul 15, 2025

Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World

Jul 15, 2025
pulisher
Jul 10, 2025

Cognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDA - Nasdaq

Jul 10, 2025
pulisher
Jul 10, 2025

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease - GlobeNewswire

Jul 10, 2025
pulisher
Jul 10, 2025

Breakthrough for Alzheimer's Treatment: FDA Meeting Clears Path for Zervimesine Phase 3 Program - Stock Titan

Jul 10, 2025
pulisher
Jul 09, 2025

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity - Yahoo Finance

Jul 09, 2025
pulisher
Jul 08, 2025

Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World

Jul 08, 2025
pulisher
Jul 08, 2025

Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate - Business Wire

Jul 08, 2025
pulisher
Jul 07, 2025

Apogee Therapeutics Announces Positive 16-Week Data from - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

New Atopic Dermatitis Drug Shows Record-Breaking 67% Success Rate, Could Reduce Injections to Just 4 Times Per Year - Stock Titan

Jul 07, 2025
pulisher
Jul 06, 2025

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 - GlobeNewswire

Jul 06, 2025
pulisher
Jul 04, 2025

Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data - Benzinga

Jul 04, 2025
pulisher
Jul 03, 2025

Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details - Business Standard

Jul 03, 2025
pulisher
Jul 02, 2025

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement - GlobeNewswire

Jul 02, 2025
pulisher
Jul 01, 2025

Cognition Therapeutics Reports Over 50% Enrollment in Phase 2 START Study for Alzheimer's Treatment - Nasdaq

Jul 01, 2025
pulisher
Jun 30, 2025

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program - BioSpace

Jun 30, 2025
pulisher
Jun 27, 2025

Allarity Therapeutics Announces Dosing of Second Patient in - GlobeNewswire

Jun 27, 2025
pulisher
Jun 25, 2025

Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001 - Ophthalmology Times

Jun 25, 2025
pulisher
Jun 24, 2025

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire

Jun 24, 2025
pulisher
Jun 23, 2025

Cidara Therapeutics Announces Positive Topline Results from - GlobeNewswire

Jun 23, 2025
pulisher
Jun 20, 2025

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO - GlobeNewswire

Jun 20, 2025
pulisher
Jun 17, 2025

$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan

Jun 17, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire

Jun 14, 2025
pulisher
Jun 13, 2025

Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace

Jun 13, 2025

An 2 Therapeutics Inc Stock (ANTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

An 2 Therapeutics Inc Stock (ANTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Easom Eric
Chief Executive Officer
Jun 02 '25
Buy
1.07
10,000
10,665
256,380
Leonard Braden Michael
10% Owner
May 28 '25
Sale
1.16
2,100,000
2,436,000
3,649,432
Leonard Braden Michael
10% Owner
May 30 '25
Sale
1.01
432,000
436,477
3,217,432
FitzPatrick Margaret M
Director
May 28 '25
Buy
1.18
8,610
10,133
8,610
Day Lucy
Chief Financial Officer
Jan 03 '25
Sale
1.34
2,957
3,965
32,670
Chanda Sanjay
Chief Development Officer
Jan 03 '25
Sale
1.34
2,957
3,965
29,824
Prior Stephen David
Chief Strategy Officer
Jan 03 '25
Sale
1.34
2,029
2,721
33,313
Eizen Joshua M
See Remarks
Jan 03 '25
Sale
1.34
9,663
12,958
116,672
Readnour Robin Shane
Director
Dec 09 '24
Buy
1.43
30,772
43,984
647,573
Readnour Robin Shane
Director
Dec 06 '24
Buy
1.45
19,228
27,795
629,090
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):